Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.40
- Piotroski Score 1.00
- Grade Buy
- Symbol (ALEC)
- Company Alector, Inc.
- Price $5.00
- Changes Percentage (-5.12%)
- Change -$0.27
- Day Low $4.82
- Day High $5.17
- Year High $8.90
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.39
- Trailing P/E Ratio -3.14
- Forward P/E Ratio -3.14
- P/E Growth -3.14
- Net Income $-130,391,000
Income Statement
Quarterly
Annual
Latest News of ALEC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Alec Baldwin delivered major win in 'Rust' shooting case
A judge in New Mexico denied reinstating criminal charges against Alec Baldwin in the Rust shooting case. The case against him was dismissed due to withheld evidence. Rust armorer Hannah Gutierrez-Ree...
By Newsweek | 1 week ago -
Judge in Alec Baldwin's Rust Trial Declines to Reconsider Her Decision to Dismiss the Case
Tommy McArdle, an editorial assistant at PEOPLE, reported that the judge in Alec Baldwin's Rust trial refused to reconsider dismissing the involuntary manslaughter case against him. The defense claime...
By PEOPLE.com | 1 week ago -
Judge declines to reconsider criminal charges against Alec Baldwin in 'Rust' shooting - National | Globalnews.ca
A New Mexico judge upheld the dismissal of involuntary manslaughter charges against Alec Baldwin in the shooting of cinematographer Halyna Hutchins on a film set. The judge rejected prosecutors' argum...
By Global News | 1 week ago
